Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 210

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Prevention of liver cancer cachexia-induced cardiac wasting and heart failure

Open access
Springer, Jochen, Tschirner, Anika, Haghikia, Arash, von Haehling, Stephan, Lal, Hind, Grzesiak, Aleksandra, Kaschina, Elena, Palus, Sandra, Pötsch, Mareike, von Websky, Karoline, Hocher, Berthold, Latouche, Celine, Jaisser, Frederic, Morawietz, Lars, Coats, Andrew J.S., Beadle, John, Argiles, Josep M., Thum, Thomas, Földes, Gabor, Doehner, Wolfram, Hilfiker-Kleiner, Denise, Force, Thomas, Anker, Stefan D. · 2014 · European Heart Journal

Abstract

AIMS: Symptoms of cancer cachexia (CC) include fatigue, shortness of breath, and impaired exercise capacity, which are also hallmark symptoms of heart failure (HF). Herein, we evaluate the effects of drugs commonly used to treat HF (bisoprolol, imidapril, spironolactone) on development of cardiac wasting, HF, and death in the rat hepatoma CC model (AH-130). METHODS AND RESULTS: Tumour-bearing rats showed a progressive loss of body weight and left-ventricular (LV) mass that was associated with a progressive deterioration in cardiac function. Strikingly, bisoprolol and spironolactone significantly reduced wasting of LV mass, attenuated cardiac dysfunction, and improved survival. In contrast, imidapril had no beneficial effect. Several key anabolic and catabolic pathways were dysregulated in the cachectic hearts and, in addition, we found enhanced fibrosis that was corrected by treatment with spironolactone. Finally, we found cardiac wasting and fibrotic remodelling in patients who died as a result of CC. In living cancer patients, with and without cachexia, serum levels of brain natriuretic peptide and aldosterone were elevated. CONCLUSION: Systemic effects of tumours lead not only to CC but also to cardiac wasting, associated with LV-dysfunction, fibrotic remodelling, and increased mortality. These adverse effects of the tumour on the heart and on survival can be mitigated by treatment with either the β-blocker bisoprolol or the aldosterone antagonist spironolactone. We suggest that clinical trials employing these agents be considered to attempt to limit this devastating complication of cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/eht302

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 210

Metadata

Authors
Springer, J., Tschirner, A., Haghikia, A., von Haehling, S., Lal, H., Grzesiak, A., Kaschina, E., Palus, S., Pötsch, M., von Websky, K., Hocher, B., Latouche, C., Jaisser, F., Morawietz, L., Coats, A. J. S., Beadle, J., Argiles, J. M., Thum, T., Földes, G., Doehner, W., Hilfiker-Kleiner, D., Force, T., & Anker, S. D.
Venue
European Heart Journal
Published
2013-08-29
Volume
35
Issue
14
Pages
932-941
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2106221209
Cited by
210
References
4
FWCI
8.90
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. https://app.cochat.ai/papers/10.1093/eurheartj/eht302
The paper
Springer, J., Tschirner, A., Haghikia, A., von Haehling, S., Lal, H., Grzesiak, A., Kaschina, E., Palus, S., Pötsch, M., von Websky, K., Hocher, B., Latouche, C., Jaisser, F., Morawietz, L., Coats, A. J. S., Beadle, J., Argiles, J. M., Thum, T., Földes, G., . . . Anker, S. D. (2014). Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. European Heart Journal. https://doi.org/10.1093/eurheartj/eht302

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.